	US 11,730,808 B2
	HBV vaccines and methods treating HBV
Scott J. Balsitis, Moss Beach, CA (US); Sarah M. Ahmadi-Erber, Vienna (AT); Timo Schippers, Vienna (AT); and Sarah Schmidt, Vienna (AT)
Assigned to Gilead Sciences, Inc., Foster City, CA (US)
Filed by Gilead Sciences, Inc., Foster City, CA (US)
Filed on Oct. 3, 2022, as Appl. No. 17/937,567.
Application 17/937,567 is a continuation of application No. 17/034,706, filed on Sep. 28, 2020, granted, now 11,497,808.
Claims priority of provisional application 62/908,494, filed on Sep. 30, 2019.
Prior Publication US 2023/0114007 A1, Apr. 13, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/29 (2006.01); A61P 37/04 (2006.01); C12N 9/12 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/292 (2013.01) [A61P 37/04 (2018.01); C12N 9/1252 (2013.01); C12Y 207/07007 (2013.01); A61K 2039/5256 (2013.01); C12N 2730/10122 (2013.01); C12N 2730/10134 (2013.01); C12N 2760/10034 (2013.01); C12N 2760/10043 (2013.01)]

25 Claims

1. A truncated hepatitis B virus (HBV) polymerase polypeptide comprising an inactivated reverse transcriptase domain and an inactivated RNase H, wherein the polypeptide is no longer than 600 amino acids in length and does not comprise all of the terminal protein (TP) domain and does not comprise all or part of the Spacer domain, wherein the polypeptide comprises or consists of an amino acid sequence of any one of SEQ ID NOs: 13-14.